肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

AACR19：Actimab-A和Venetoclax具有协同作用

2019-04-04 不详 网络

Actimab-Avenetoclax放射性同位素
关注

Actinium制药公司在2019年美国癌症研究协会（AACR）年会中证明，靶向CD33阳性细胞的Actimab-A能够显著降低MCL-1水平，从而使它们对venetoclax更为敏感。

Actinium制药公司在2019年美国癌症研究协会（AACR）年会中证明，靶向CD33阳性细胞的Actimab-A能够显著降低MCL-1水平，从而使它们对venetoclax更为敏感。Actimab-A是由抗CD33单克隆抗体lintuzumab和α粒子放射性同位素Actinium-225组成。Venetoclax是一种BCL-2抑制剂，并被批准用于急性髓性白血病、慢性淋巴细胞白血病和小淋巴细胞白血病患者。

本次展示关键内容如下：

1. MCL-1是BCL-2抗凋亡蛋白家族中的一种蛋白质，其在复发或难治性AML细胞中过度表达，并介导对venetoclax的抗性。Actimab-A能够降低venetoclax抗性AML细胞中MCL-1的水平。

2. BCL-XL是BCL-2家族中的另一种蛋白质，也被提出用于介导对venetoclax的抗性。Actimab-A也能够降低venetoclax抗性AML细胞中BCL-XL的水平。


原始出处：

http://www.firstwordpharma.com/node/1633305#axzz5k7bIYvN6

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912113, encodeId=1b8b191211326, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 14 21:26:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734126, encodeId=576f1e3412693, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 16 13:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400421, encodeId=cc41140042132, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551992, encodeId=516c15519925b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-11-14 snf701207

    #mAb#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1912113, encodeId=1b8b191211326, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 14 21:26:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734126, encodeId=576f1e3412693, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 16 13:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400421, encodeId=cc41140042132, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551992, encodeId=516c15519925b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-05-16 canlab

    #NET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912113, encodeId=1b8b191211326, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 14 21:26:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734126, encodeId=576f1e3412693, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 16 13:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400421, encodeId=cc41140042132, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551992, encodeId=516c15519925b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 10518094zz

    #ACR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912113, encodeId=1b8b191211326, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 14 21:26:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734126, encodeId=576f1e3412693, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu May 16 13:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400421, encodeId=cc41140042132, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551992, encodeId=516c15519925b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Apr 06 10:26:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 Luyuxie_14

    #AACR#

    0